Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Atara Biotherapeutics Inc    ATRA

ATARA BIOTHERAPEUTICS INC (ATRA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/11/2018 07/12/2018 07/13/2018 07/16/2018 07/17/2018 Date
40.65(c) 41.7(c) 39.95(c) 38.5(c) 40.5 Last
380 293 408 780 371 142 332 790 307 161 Volume
+0.99% +2.58% -4.20% -3.63% +5.19% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -174 M
Net income 2018 -168 M
Finance 2018 360 M
Yield 2018 -
Sales 2019 0,83 M
EBIT 2019 -213 M
Net income 2019 -199 M
Finance 2019 489 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 0
EV / Sales2019 1 534x
Capitalization 1 756 M
More Financials
Company
Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology.Its product candidates are biologics targeting myostatin and activin, members of the... 
More about the company
Surperformance© ratings of Atara Biotherapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ATARA BIOTHERAPEUTICS INC
07/12Free Pre-Market Technical Recap on ArQule and Three Additional Biotech
AC
06/25ATARA BIOTHERAPEUTICS : Opens State-of-the-Art Operations and Manufacturing Faci..
AQ
06/18ATARA BIOTHERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holder..
AQ
06/15ATARA BIOTHERAPEUTICS : rsquo; Tab-cel™ Achieves Positive Long-Term Outcom..
AQ
06/14ATARA BIOTHERAPEUTICS : Announces Publication of New Research Linking Epstein-Ba..
AQ
06/13ATARA BIOTHERAPEUTICS : Announces Publication of New Research Linking Epstein-Ba..
AQ
06/08ATARA BIOTHERAPEUTICS, INC. (NASDAQ : ATRA) Files An 8-K Departure of Directors ..
AQ
06/07ATARA BIOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-..
AQ
06/07Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 563..
GL
06/07Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financ..
GL
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/13Isaac E. Ciechanover Sells 58,400 Shares of Atara Biotherapeutics Inc $ATRA S.. 
07/12Atara Biotherapeutics $ATRA Stock Rating Upgraded by Zacks Investment Researc.. 
07/12Insider Selling: Atara Biotherapeutics Inc $ATRA CEO Sells 58,400 Shares of S.. 
07/11Atara Biotherapeutics $ATRA Upgraded to Hold by Zacks Investment Research  
07/11$ABEO $ATRA $BLUE $BOLD $CLLS $CRSP $EDIT $FIXX $NTLA $ONCE $QURE $RGNX $SGMO.. 
More tweets
Qtime:76
News from SeekingAlpha
07/10GENOMIC MEDICINE Q2 2018 : Do Earnings Matter? 
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/22ATARA BIOTHERAPEUTICS : 2 New Catalysts To Fuel Further Growth 
06/193 THINGS IN BIOTECH, JUNE 18 : Some More Good Heme News! 
06/15Atara Bio's tab-cell shows durable effect in mid-stage studies in EBV-associa.. 
Chart ATARA BIOTHERAPEUTICS INC
Duration : Period :
Atara Biotherapeutics Inc Technical Analysis Chart | ATRA | US0465131078 | 4-Traders
Technical analysis trends ATARA BIOTHERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 45,8 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Issac E. Ciechanover Chairman, President & Chief Executive Officer
Utpal Koppikar Chief Financial Officer
Christopher M. Haqq Chief Scientific Officer, Executive VP-R&D
Joe Newell Chief Technical Operations Officer & Executive VP
Kanya Rajangam Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ATARA BIOTHERAPEUTICS INC112.71%1 756
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.93%10 467
NEUROCRINE BIOSCIENCES, INC.32.61%9 250